Tyra Biosciences, Inc. Stock Price, News & Analysis

Tyra Biosciences (NASDAQ: TYRA) reported Q1 2025 financial results and corporate updates. The company has $318.9 million in cash and equivalents, providing runway through 2027. Key developments include: 1) Advancement of TYRA-300: - BEACH301 study for pediatric achondroplasia now enrolling - SURF302 Phase 2 study for bladder cancer preparing to start - Published positive preclinical results in JCI Insight 2) Progress with other programs: - TYRA-200: Continuing Phase 1 SURF201 study for cholangiocarcinoma - TYRA-430: Initiated patient dosing in SURF431 study for liver cancer Financial highlights show Q1 2025 net loss of $28.1 million vs $18.2 million in Q1 2024. R&D expenses increased to $25.0 million from $17.2 million, while G&A expenses rose to $6.9 million from $5.1 million.

Tyra Biosciences (NASDAQ: TYRA) reported its Q4 and full year 2024 financial results, highlighting significant progress in its precision medicine pipeline. The company ended 2024 with $341.4 million in cash and equivalents, providing runway through 2027.

Key developments include three FDA-cleared INDs for TYRA's precision small molecules, with TYRA-300 advancing to three Phase 2 studies: SURF302 for bladder cancer, BEACH301 for pediatric achondroplasia, and SURF301 for metastatic urothelial cancer. Notably, SURF301 showed promising interim results with 54.5% of patients achieving confirmed partial response.

Financial results show Q4 2024 net loss of $25.6 million compared to $22.8 million in Q4 2023. Full-year 2024 net loss was $86.5 million. R&D expenses increased to $80.1 million for 2024, up from $62.5 million in 2023.

Tyra Biosciences (NASDAQ: TYRA), a clinical-stage biotechnology company specializing in Fibroblast Growth Factor Receptor (FGFR) biology, has announced its participation in four major upcoming investor conferences in early 2025.

The company will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (February 11-12, virtual), the TD Cowen 45th Annual Healthcare Conference (March 3-5, Boston), the Jefferies Biotech on the Beach Summit (March 11-12, Miami), and the Barclays 27th Annual Global Healthcare Conference (March 11-13, Miami).

Management will engage in fireside chats and one-on-one investor meetings at most events, with presentations scheduled for February 12 at 2:00 PM ET (Oppenheimer), March 3 at 9:50 AM ET (TD Cowen), and March 12 at 8:30 AM ET (Barclays). Live and archived webcasts of the fireside chats will be accessible through TYRA's investor relations website.

Tyra Biosciences (Nasdaq: TYRA) has appointed Adele Gulfo to its Board of Directors. Gulfo brings nearly three decades of executive leadership experience in pharmaceutical development and commercialization from companies including Pfizer, AstraZeneca, Viatris, and Sumitomo Pharma.

Most recently, Gulfo served as CEO of Sumitomo Pharma America's Biopharma Commercial Unit, overseeing portfolios in oncology, rare disease, urology, CNS, and Women's Health. Her notable achievements include leading Pfizer's $12B+ U.S. primary care business unit and playing key roles in launching successful drugs like LIPITOR® and CRESTOR®.

The appointment aims to strengthen TYRA's development of precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, particularly as the company advances TYRA-300 for non-muscle invasive bladder cancer.

Tyra Biosciences (Nasdaq: TYRA) announced the acceptance of two abstracts for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco. The first presentation covers TYRA-200, featuring a multicenter, open-label, first-in-human study for advanced intrahepatic cholangiocarcinoma and other solid tumors with FGFR2 gene alterations. Dr. Robin Kate Kelley from UC San Francisco will present this study.

The second presentation focuses on TYRA-430, described as the first reversible FGFR4/3 inhibitor designed to address challenges in FGF19-driven hepatocellular carcinoma treatment, to be presented by Dr. Ronald Swanson. Both presentations are scheduled for January 24, 2025, from 11:30 AM to 1:00 PM PST.

Tyra Biosciences (NASDAQ: TYRA) has received FDA clearance for its IND application to proceed with a Phase 2 clinical trial of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC). The company has appointed Dr. Erik Goluboff as SVP of Clinical Development to lead this program.

The Phase 2 study, SURF302, will evaluate TYRA-300, an oral FGFR3-selective inhibitor, in up to 90 participants across multiple U.S. sites. Participants will be randomized to receive either 50mg or 60mg once-daily doses. The primary endpoint is complete response rate at three months, with secondary endpoints including time to recurrence, duration of response, and safety measures.

TYRA-300 targets FGFR3, which is altered in 60-80% of IR NMIBC cases. The first patient is expected to be dosed in Q2 2025. The drug will also be evaluated in two other Phase 2 studies: BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial carcinoma.

Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotechnology company specializing in Fibroblast Growth Factor Receptor (FGFR) precision medicines, has announced its participation in two major investor conferences. CEO Todd Harris will present at the Jefferies London Healthcare Conference (November 19-21st, 2024) with a fireside chat on November 19th at 2:00 pm GMT, and at the 36th Annual Piper Healthcare Conference (December 3-5th, 2024) in New York with a presentation on December 4th at 10:30 am ET. Management will participate in one-on-one investor meetings at both events. Webcasts will be available on TYRA's website.

Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotechnology company, reported its Q3 2024 financial results and corporate highlights. Key points include positive interim clinical proof-of-concept results for TYRA-300 in metastatic urothelial cancer (mUC) from the SURF301 Phase 1/2 study. The company received IND clearance for a Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) and plans to submit an IND for a Phase 2 study in non-muscle invasive bladder cancer (NMIBC) by year-end 2024.

Tyra also advanced its TYRA-200 and TYRA-430 programs and appointed Dr. Doug Warner as Chief Medical Officer. Financially, Tyra reported a net loss of $24.0 million for Q3 2024, with increased R&D and administrative expenses. The company holds $360.1 million in cash and equivalents, expected to fund operations through 2026.

Tyra Biosciences received FDA clearance for its IND application to proceed with BEACH301, a Phase 2 clinical trial of TYRA-300 in pediatric achondroplasia. TYRA-300 is the first oral FGFR3-selective inhibitor well-tolerated in clinical studies. The trial will evaluate children ages 3-10 with achondroplasia, enrolling up to 10 participants per dose level in treatment-naïve and previously treated cohorts. The study aims to assess safety, tolerability, and changes in growth velocity. First patient dosing is expected in Q1 2025. TYRA-300 received both Orphan Drug and Rare Pediatric Designations from the FDA for achondroplasia treatment.